Medtech wins & commercialization
A cluster of commercialization and recognition stories hit this week: BrainsWay completed a $6M milestone investment in Neurolief after FDA clearance of Proliv™Rx for depression, Francis Medical reported its first East‑Coast Vanquish® water‑vapor prostate ablation procedure, and ROMTech landed a LexisNexis Top‑100 Innovators spot. Together they show how clearance, first commercial procedures, and IP recognition drive capital and market momentum. (manilatimes.net) (prnewswire.com 1) (prnewswire.com 2)
BrainsWay filed its March 26, 2026 Form 6‑K stating the company has invested $11 million in Neurolief to date and holds a call option to acquire Neurolief’s outstanding equity under defined exercise windows. (sec.gov) The same filing details potential additional milestone funding beyond the initial tranches, including a conditional third tranche of up to $5 million tied to revenue targets and convertible‑loan terms. (sec.gov) Neurolief’s Proliv™Rx received FDA Premarket Approval on January 12, 2026 as a Class III, physician‑directed at‑home adjunctive therapy for adults with major depressive disorder who failed at least one antidepressant. (prnewswire.com) Francis Medical’s March 25, 2026 announcement identifies Dr. Robert Given of Urology of Virginia as the clinician who performed the East‑Coast commercial Vanquish® procedure at Chesapeake Regional Surgery Center. (prnewswire.com) Francis Medical had previously reported its first U.S. commercial Vanquish case at Pinnacle Surgery Center in Austin, Texas, performed by Dr. Eric Giesler on February 3, 2026 as part of initial real‑world rollouts. (prnewswire.com) The Vanquish® System was cleared via 510(k) in November 2025, a clearance supported by 12‑month follow‑up on the initial 110 patients in the company’s VAPOR 2 prospective study — which is enrolling 235 patients across 26 U.S. sites. (francismedical.com) ROM Technologies (ROMTech) announced March 25, 2026 that it was named to LexisNexis’ Top 100 Global Innovators for 2026, noting the company was founded 13 years ago and is the only privately held medtech on this year’s list based on its patent portfolio. (prnewswire.com) LexisNexis says the Top 100 selection is driven by measurable improvement in patent portfolios over the prior two years and the 2026 roster includes major companies such as Johnson & Johnson, Intuitive Surgical, and Stryker. (lexisnexisip.com)
